Prostate Cancer - Results from #27760

Expression of hedgehog pathway components in prostate carcinoma microenvironment: Shifting the balance towards autocrine signalling - Abstract July 18, 2011

The impact of PSA testing frequency on prostate cancer incidence and treatment in older men - Abstract July 18, 2011

Assessing response in bone metastases in prostate cancer with diffusion weighted MRI - Abstract July 18, 2011

Prostate-specific antigen 1.5-4.0 ng/mL: A diagnostic challenge and danger zone - Abstract July 18, 2011

Location of residual cancer after transrectal high-intensity focused ultrasound ablation for clinically localized prostate cancer - Abstract July 18, 2011

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: Results of the French Genito-Urinary Tumor Group (GETUG) P01 trial July 18, 2011

Editor's Commentary - Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: Results of the French Genito-Urinary Tumor Gr July 18, 2011

Editor's Commentary - The relationship between prostate specific antigen change and biopsy progression in patients with prostate cancer on active surveillance July 18, 2011

Single-arc volumetric-modulated arc therapy can provide dose distributions equivalent to fixed-beam intensity-modulated radiation therapy for prostatic irradiation with seminal vesicle and/or lymph node involvement - Abstract July 17, 2011

The role of vitamin D, estrogen, calcium sensing receptor genotypes and serum calcium in the pathogenesis of prostate cancer - Abstract July 15, 2011

Potential prostate cancer drug target: Bioactivation of androstanediol by conversion to dihydrotestosterone - Abstract July 15, 2011

Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer - Abstract July 15, 2011

Predictive models for worsening prognosis in potential candidates for active surveillance of presumed low-risk prostate cancer - Abstract July 15, 2011

Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer - Abstract July 15, 2011

Diabetes and prostate cancer risk in the REDUCE trial - Abstract July 15, 2011

Lateral spine radiographs before androgen deprivation treatment detect a high incidence of undiagnosed vertebral fragility fractures in men with advanced prostate cancer - Abstract July 14, 2011

Multi-parametric magnetic resonance imaging to rule-in and rule-out clinically important prostate cancer in men at risk: A cohort study - Abstract July 14, 2011

New findings in localized and advanced prostate cancer: AUA 2011 review - Abstract July 14, 2011

Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy - Abstract July 14, 2011

The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: Evaluation and optimization in patients at higher risk of relapse - Abstract July 14, 2011

Page 1389 of 1450